ForSight VISION5 is focused on developing non-invasive products that replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy. ForSight VISION5’s lead product candidate is the Helios(TM) insert, a novel, non-invasive delivery system designed to allow glaucoma and ocular hypertensive patients to continually receive their medication.
Location: United States, California, Menlo Park
Employees: 51-200
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | Delphi Ven... | delphivent... |
Mentions in press and media 2
| Date | Title | Description |
| 12.09.2016 | With small RetroSense deal, Allergan hoping for big win | RP is a group of congenital retinal diseases driven by mutations in the rhodopsin gene. The disease initially impacts retinal cells called rods, which provide peripheral and night vision. As the rods degenerate, neighboring cones, which all... |
| - | With small RetroSense deal, Allergan hoping for big win | Allergan’s recent deal for gene therapy company RetroSense Therapeutics, based in Ann Arbor, Michigan, could be a nice win for the big biotech. For $60 million, and potential milestone payments down the line, Allergan picks up the developme... |